PLEDGE AGREEMENTPledge Agreement • March 4th, 2020 • RedHill Biopharma Ltd. • Pharmaceutical preparations
THIS PLEDGE AGREEMENT dated as of February 23, 2020 (as amended, modified, restated or supplemented from time to time, this “Pledge Agreement”) is by and among the parties identified as “Pledgors” on the signature pages hereto and such other parties as may become Pledgors hereunder after the date hereof (individually a “Pledgor”, and collectively, the “Pledgors”) and HCR Collateral Management, LLC, as administrative agent (in such capacity, the “Administrative Agent”) for the Secured Parties (defined below).
SECURITY AGREEMENTSecurity Agreement • March 4th, 2020 • RedHill Biopharma Ltd. • Pharmaceutical preparations
THIS SECURITY AGREEMENT dated as of February 23, 2020 (as amended, modified, restated or supplemented from time to time, this “Security Agreement”) is by and among the parties identified as “Grantors” on the signature pages hereto and such other parties as may become Grantors hereunder after the date hereof (individually a “Grantor”, and collectively the “Grantors”) and HCR Collateral Management, LLC, as administrative agent (in such capacity, the “Administrative Agent”) for the Secured Parties (defined below).
LICENSE AGREEMENTLicense Agreement • March 4th, 2020 • RedHill Biopharma Ltd. • Pharmaceutical preparations • New York
CREDIT AGREEMENT Dated as of February 23, 2020 among REDHILL BIOPHARMA INC., as the Borrower, REDHILL BIOPHARMA LTD., as a Guarantor, HCR COLLATERAL MANAGEMENT, LLC, as the Administrative Agent and THE LENDERS FROM TIME TO TIME PARTY HERETOCredit Agreement • March 4th, 2020 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This CREDIT AGREEMENT is entered into as of February 23, 2020 among REDHILL BIOPHARMA INC., a Delaware corporation (the “Borrower”), REDHILL BIOPHARMA LTD., a company incorporated under the laws of the State of Israel, as Guarantor (“RedHill Parent”), the Lenders (defined herein), HCR Collateral Management, LLC, as Administrative Agent and those additional entities that hereafter become parties hereto in accordance with the terms hereof by executing a Joinder Agreement.
SUBSCRIPTION AGREEMENTSubscription Agreement • March 4th, 2020 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Subscription Agreement (this “Subscription”) is dated as of October 17, 2019, by and among Redhill Biopharma Ltd., a company limited by shares organized under the laws of the State of Israel, registration number 514304005 (the “Company”), Cosmo Pharmaceuticals NV, a Dutch corporation (“Cosmo Pharma“), and Cosmo Technologies Ltd. (“Cosmo Technology“, and together with Cosmo Pharma, the “Investors"), each such Investor with a place of business at Riverside II, Sir John Rogerson’s Quay, Dublin 2, Ireland.
CONFIDENTIAL AND PRIVILEGED Dated February 23, 2020 CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED....Supply Agreement • March 4th, 2020 • RedHill Biopharma Ltd. • Pharmaceutical preparations
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 4th, 2020 • RedHill Biopharma Ltd. • Pharmaceutical preparations • London
THIS EXCLUSIVE LICENSE AGREEMENT is made and entered into as of October 17, 2019 (the “Effective Date”), by and between Cosmo Technologies Ltd., a company duly incorporated and existing under the laws of Ireland, with registered offices at Riverside II, Sir John Rogerson’s Quay, Dublin 2, Ireland (“Cosmo”) and RedHill Biopharma, Inc. a Delaware corporation, having an address at 8045 Arco Corporate Drive, Suite 120, Raleigh, North Carolina 27617 and all Affiliates thereof (“RedHill”). Cosmo and RedHill each may be referred to herein individually as a “Party,” or collectively as the “Parties”.
